Trials / Not Yet Recruiting
Not Yet RecruitingNCT04520139
Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT
Phase I Dose-Escalating and Phase II Dose-Expansion Study of N-Acetyl-Cysteine (NAC) Administration to Ovarian Cancer Patients Receiving Platinum-Based Therapy (PBT) for the Mitigation of Chemotherapy-Related Cognitive Impairment (CRCI)
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 102 (estimated)
- Sponsor
- University of California, Irvine · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I, dose-escalation and phase II dose-expansion clinical trial determining the maximum tolerated dose (MTD) and safety and tolerability of adding N-Acetyl-Cysteine (NAC) to ovarian cancer patients who are receiving a platinum-based therapy (PBT). This study will investigate whether NAC will mitigate chemotherapy-related cognitive impairment (CRCI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | N-Acetyl-Cysteine | Given PO |
| OTHER | Placebo | Given PO |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2026-12-01
- Completion
- 2027-12-01
- First posted
- 2020-08-20
- Last updated
- 2026-03-10
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04520139. Inclusion in this directory is not an endorsement.